ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1981

A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity

Wenhui Wang1, Amit Lahiri2, Teresina Laragione2, Jun Zhu1 and Percio S. Gulko2,3, 1Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, pathogenesis, rheumatoid arthritis, Synovial Immune Biology, synovium and severity

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic autoimmune joint disease. RA is pathologically heterogeneous with multiple contributing factors. While there has been a major emphasis in studies of the immune regulatory factors the gene networks regulating the synovial pathology remains incompletely understood. We aimed at establishing a RA synovial tissue gene network to identify new key regulators/driver of the synovial and fibroblast-like synoviocyte (FLS) pathology.

Methods: Several large RA synovial tissue gene expression data sets (GSE48780 and GSE21537, consisting of 83 and 62 synovial biopsies from RA patients, respectively) were used. We used a software suite that we developed, RIMBANet, to construct a Bayesian network model for RA. We computationally estimated cell composition in synovial biopsies (T cells, neutrophils, FLS, macrophages, others).

Results: Immune cell compositions in inflamed and non-inflamed synovial tissues were significantly different, with increased numbers of M1 macrophages in inflamed tissues than in non-inflamed tissues. We adjusted synovial tissue profiling data for cell composition, and combined the two data sets together used in network reconstruction. We identified 7,521 nodes representing expression levels of genes and 8,118 edges representing putative causal relationships between genes. We compared the constructed RA network with well-known interaction databases or canonical pathways, and showed that the RA network overlapped with existing network/pathways significantly better than random networks. Then, we collected a set of RA severity related gene sets from a variety of sources (FLS gene expression, rodent studies, etc) and projected them onto the RA network identified key regulators for disease severity. Top inferred key regulators included DLX4, SEMA3E, LCP1, TRIM22, and ZNF385B. To test whether the inferred key regulators have any impact on RA disease severity, we examined the role of DLX4 in FLS invasiveness, an in vitro phenotype that strongly correlates with joint damage in RA. DLX4 was expressed in RA FLS and its knockdown with siRNA in primary RA FLS significantly reduced FLS invasiveness by 80%.

Conclusion: We here describe a new RA synovial gene network. This study also provides encouraging validation of the new synovial gene network suggesting that it has the potential to lead to the discoveries and of new important genes involved in disease pathogenesis and potentially new targets for treatment.


Disclosure: W. Wang, None; A. Lahiri, None; T. Laragione, None; J. Zhu, None; P. S. Gulko, None.

To cite this abstract in AMA style:

Wang W, Lahiri A, Laragione T, Zhu J, Gulko PS. A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-molecular-bayesian-network-for-rheumatoid-arthritis-reveals-multiple-candidate-key-regulators-for-disease-severity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-molecular-bayesian-network-for-rheumatoid-arthritis-reveals-multiple-candidate-key-regulators-for-disease-severity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology